
Ribo Files European Phase 1 Trial for Obesity-Targeting siRNA RBD3133
Suzhou Ribo Life Science and its Swedish subsidiary Ribocure Pharmaceuticals have submitted a Phase 1 clinical trial application in Europe for RBD3133. The investigational siRNA therapeutic aims to treat obesity and metabolic dysfunction by silencing the INHBE gene, marking the company’s first entry into the weight-loss drug market.



















